GUFICBIO Gufic Biosciences Q1 FY26 results (Apr–Jun 2025) and concall
Gufic BioScience reported a strong Q1 FY26, driven primarily by the operational ramp-up of its Indore facility, which contributed an additional INR 25-26 crores in revenue. The company saw significant QoQ growth in revenue, EBITDA, PBT, and PAT, alongside margin expansion. Management highlighted strategic shifts in key divisions, expansion of its aesthetic and reproductive medicine portfolios, and a clear roadmap for international growth, while also addressing near-term challenges related to working capital and cash flow.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 |
|---|---|---|---|---|
| Revenue | 204 | 208 | 205 | 227 |
| EBITDA | 39 | 34 | 27 | 32 |
| Net profit | 22 | 19 | 8 | 12 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
